BIOMAT Database Logo BIOMAT Database Logo

Pharmacological Management of Diabetic Nephropathy. 2020

Vasilios Papademetriou, and Sofia Alataki, and Konstantinos Stavropoulos, and Christodoulos Papadopoulos, and Kostas Bakogiannis, and Kostas Tsioufis
VA Medical Center and Georgetown University, Washington, DC, United States.

Diabetes mellitus (DM) is one of the most common diseases worldwide. Its adverse effects on several body organs, have made treatment of DM a priority. One of the most serious complications of DM is diabetic nephropathy (DN). The aim of this review is to critically discuss available data on the pharmacological management of DN. A comprehensive review of the literature was performed to identify studies assessing the impact of several drug classes on DN. Several studies have been conducted in order to find a novel and effective treatment of DN. So far, the cornerstone therapy of DN consists of renin-angiotensin system (RAS) inhibitors, agents that decrease the synthesis of intrarenal angiotensin II or block its receptors. Their antiproteinuric and antihypertensive effects can not only decelerate the progress of DN but prevent its onset as well. Novel antidiabetic drugs, such as sodium-glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide- 1 receptor agonists (GLP-1 RA), are promising agents in the therapy of DN, due to their positive effect on renal and cardiovascular adverse events. From lipid-lowering agents, atorvastatin improves DN up to stage 3 and substantially reduces CVD. RAS inhibitors, SGLT-2i and GLP-1 agonists were found to be beneficial for the treatment of DN. Larger renal trials are needed in order to incorporate these drugs into the first line treatment of DN.

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067757 Glucagon-Like Peptide-1 Receptor A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS). GLP-1 Receptor,GLP-1R Receptor,GLP1R Protein,GLP1R Receptor,GLP 1 Receptor,GLP 1R Receptor,Glucagon Like Peptide 1 Receptor,Peptide-1 Receptor, Glucagon-Like,Protein, GLP1R,Receptor, GLP-1,Receptor, GLP-1R,Receptor, GLP1R,Receptor, Glucagon-Like Peptide-1
D000077203 Sodium-Glucose Transporter 2 Inhibitors Compounds that inhibit SODIUM-GLUCOSE TRANSPORTER 2. They lower blood sugar by preventing the reabsorption of glucose by the kidney and are used in the treatment of TYPE 2 DIABETES MELLITUS. Gliflozin,SGLT-2 Inhibitor,SGLT2 Inhibitor,Sodium-Glucose Transporter 2 Inhibitor,Gliflozins,SGLT-2 Inhibitors,SGLT2 Inhibitors,Inhibitor, SGLT-2,Inhibitor, SGLT2,SGLT 2 Inhibitor,SGLT 2 Inhibitors,Sodium Glucose Transporter 2 Inhibitor,Sodium Glucose Transporter 2 Inhibitors
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Vasilios Papademetriou, and Sofia Alataki, and Konstantinos Stavropoulos, and Christodoulos Papadopoulos, and Kostas Bakogiannis, and Kostas Tsioufis
Pharmacological management of membranous nephropathy.
March 2002, Current opinion in nephrology and hypertension,
Vasilios Papademetriou, and Sofia Alataki, and Konstantinos Stavropoulos, and Christodoulos Papadopoulos, and Kostas Bakogiannis, and Kostas Tsioufis
[Management of diabetic nephropathy].
September 1997, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Vasilios Papademetriou, and Sofia Alataki, and Konstantinos Stavropoulos, and Christodoulos Papadopoulos, and Kostas Bakogiannis, and Kostas Tsioufis
Management of diabetic nephropathy.
May 2001, Journal of the Royal Society of Medicine,
Vasilios Papademetriou, and Sofia Alataki, and Konstantinos Stavropoulos, and Christodoulos Papadopoulos, and Kostas Bakogiannis, and Kostas Tsioufis
[Pharmacological prevention and treatment of diabetic nephropathy].
January 1993, Duodecim; laaketieteellinen aikakauskirja,
Vasilios Papademetriou, and Sofia Alataki, and Konstantinos Stavropoulos, and Christodoulos Papadopoulos, and Kostas Bakogiannis, and Kostas Tsioufis
Management of early diabetic nephropathy.
April 1997, The American journal of medicine,
Vasilios Papademetriou, and Sofia Alataki, and Konstantinos Stavropoulos, and Christodoulos Papadopoulos, and Kostas Bakogiannis, and Kostas Tsioufis
Clinical management of diabetic nephropathy.
November 1999, Diabetes, obesity & metabolism,
Vasilios Papademetriou, and Sofia Alataki, and Konstantinos Stavropoulos, and Christodoulos Papadopoulos, and Kostas Bakogiannis, and Kostas Tsioufis
Pharmacologic management of diabetic nephropathy.
November 2002, Clinical therapeutics,
Vasilios Papademetriou, and Sofia Alataki, and Konstantinos Stavropoulos, and Christodoulos Papadopoulos, and Kostas Bakogiannis, and Kostas Tsioufis
Pharmacological management of diabetic dyslipidemia.
February 2017, Expert review of clinical pharmacology,
Vasilios Papademetriou, and Sofia Alataki, and Konstantinos Stavropoulos, and Christodoulos Papadopoulos, and Kostas Bakogiannis, and Kostas Tsioufis
Diabetic nephropathy-pathophysiology and management.
January 2002, International urology and nephrology,
Vasilios Papademetriou, and Sofia Alataki, and Konstantinos Stavropoulos, and Christodoulos Papadopoulos, and Kostas Bakogiannis, and Kostas Tsioufis
The changing management of diabetic nephropathy.
May 1995, Hospital practice (1995),
Copied contents to your clipboard!